Ritu Baral
Stock Analyst at TD Cowen
(1.63)
# 3,347
Out of 4,975 analysts
32
Total ratings
39.29%
Success rate
-2.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $390 → $554 | $432.53 | +28.08% | 2 | Aug 26, 2025 | |
| AKRO Akero Therapeutics | Initiates: Buy | $76 | $44.72 | +69.95% | 1 | Aug 4, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $44 | $55.74 | -21.06% | 1 | Feb 5, 2025 | |
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $2.15 | - | 4 | Nov 18, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: Hold | n/a | $1.26 | - | 2 | Nov 18, 2024 | |
| RNA Avidity Biosciences | Maintains: Buy | $56 → $78 | $50.36 | +54.88% | 1 | Oct 21, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $282 → $371 | $452.00 | -17.92% | 4 | Oct 21, 2024 | |
| INSM Insmed | Maintains: Buy | $75 → $98 | $145.10 | -32.46% | 3 | Aug 9, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $7.11 | - | 1 | Aug 8, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $125 → $175 | $18.71 | +835.33% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $21 | $25.26 | -16.86% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.61 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.09 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.57 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $24.19 | - | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.22 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.86 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.43 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $728.41 | - | 2 | Jan 12, 2018 |
Madrigal Pharmaceuticals
Aug 26, 2025
Maintains: Buy
Price Target: $390 → $554
Current: $432.53
Upside: +28.08%
Akero Therapeutics
Aug 4, 2025
Initiates: Buy
Price Target: $76
Current: $44.72
Upside: +69.95%
Palvella Therapeutics
Feb 5, 2025
Initiates: Buy
Price Target: $44
Current: $55.74
Upside: -21.06%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.15
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.26
Upside: -
Avidity Biosciences
Oct 21, 2024
Maintains: Buy
Price Target: $56 → $78
Current: $50.36
Upside: +54.88%
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $452.00
Upside: -17.92%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $75 → $98
Current: $145.10
Upside: -32.46%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $7.11
Upside: -
Sarepta Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $18.71
Upside: +835.33%
Aug 8, 2022
Maintains: Outperform
Price Target: $32 → $21
Current: $25.26
Upside: -16.86%
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.61
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $14.09
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.57
Upside: -
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $24.19
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.22
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.86
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $0.43
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $728.41
Upside: -